CSF1R and pancreatic neoplasm: In addition, blockade of CSF-1/CSF1-R by mAb anti-CSF1 or with PLX2297 (a small molecule targeting the tyrosine kinase domain of CSF1-R) was reported to reprogram remaining TAMs at the tumor site to support antitumor immunity in pancreatic cancer mouse models (58).